Venetoclax retreatment of patients with chronic lymphocytic leukemia after a previous venetoclax-based regimen

Detalles Bibliográficos
Autores principales: Thompson, Meghan C., Harrup, Rosemary A., Coombs, Catherine C., Roeker, Lindsey E., Pu, Jeffrey J., Choi, Michael Y., Barr, Paul M., Allan, John N., Šimkovič, Martin, Leslie, Lori, Rhodes, Joanna, Chong, Elise A., Kamdar, Manali, Skarbnik, Alan, Lansigan, Frederick, McCall, Brittany, Saja, Khalid, Dyer, Martin J.S., Walter, Harriet S., Lefebure, Marcus, Thadani-Mulero, Maria, Boyer, Michelle, Biondo, Juliana, Sail, Kavita, Manzoor, Beenish S., Furman, Richard, Bantilan, Kurt S., Goy, Andre, Feldman, Tatyana, Labella, Dominic, Schuster, Stephen J., Park, Jae, Palomba, Lia, Zelenetz, Andrew, Eyre, Toby A., Kater, Arnon P., Seymour, John F., Mato, Anthony R.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The American Society of Hematology 2022
Materias:
Research Letter
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9636322/
https://www.ncbi.nlm.nih.gov/pubmed/35736670
http://dx.doi.org/10.1182/bloodadvances.2022007812

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9636322/
https://www.ncbi.nlm.nih.gov/pubmed/35736670
http://dx.doi.org/10.1182/bloodadvances.2022007812

Ejemplares similares